Brivaracetam single and multiple rising oral dose study in healthy Japanese Participants: Influence of CYP2C19 genotype

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 5, 2014, Pages 394-399

  Stockis, Armel ^a   Watanabe, Shikiko ^a   Rouits, Elisabeth ^a   Matsuguma, Kyoko ^b   Irie, Shin ^b  

^a UCB PHARMA   (Belgium)

^b Kyushu Clinical Pharmacology Research Clinic   (Japan)

Author keywords

Anticonvulsants; Clinical pharmacology; CYP2C19; Drug clearance; Pharmacokinetics

Indexed keywords

ACID; BRIVARACETAM; CYTOCHROME P450 2C19; HYDROXYACID; PLACEBO; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYP2C19 GENE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ETHNIC DIFFERENCE; EUROPEAN; EVENING DOSAGE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDROLYSIS; HYDROXYLATION; JAPANESE (PEOPLE); MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; URINE LEVEL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; GENETICS; JAPAN; METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2C19; DOUBLE-BLIND METHOD; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; JAPAN; MALE; PYRROLIDINONES; YOUNG ADULT;

EID: 84908237589     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-14-RG-010     Document Type: Article

References (20)

1. Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T. and White, H. S.: Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res., 103: 2-30 (2013).
2. Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., et al.: Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem., 47: 530-549 (2004).
3. Matagne, A., Margineanu, D.-G., Kenda, B., Michel, P. and Klitgaard, H.: Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol., 154: 1662-1671 (2008).
4. French, J. A., Costantini, C., Brodsky, A. and von Rosenstiel, P.: Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology, 75: 519-525 (2010).
5. Van Paesschen, W., Hirsch, E., Johnson, M., Falter, U. and von Rosenstiel, P.: Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial. Epilepsia, 54: 89-97 (2013).
6. Kwan, P., Trinka, E., Van Paesschen, W., Rektor, I., Johnson, M. E. and Lu, S.: Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia, 55: 38-46 (2014).
7. Ryvlin, P., Werhahn, K. J., Blaszczyk, B., Johnson, M. E. and Lu, S.: Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia, 55: 47-56 (2014).
8. Biton, V., Berkovic, S. F., Abou-Khalil, B., Sperling, M. R., Johnson, M. E. and Lu, S.: Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial. Epilepsia, 55: 57-66 (2014).
9. Rolan, P., Sargentini-Maier, M. L., Pigeolet, E. and Stockis, A.: The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br. J. Clin. Pharmacol., 66: 71-75 (2008).
10. Sargentini-Maier, M. L., Rolan, P., Connell, J., Tytgat, D., Jacobs, T., Pigeolet, E., Riethuisen, J. M. and Stockis, A.: The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol., 63: 680-688 (2007).
11. Sargentini-Maier, M. L., Sokalski, A., Boulanger, P., Jacobs, T. and Stockis, A.: Brivaracetam disposition in renal impairment. J. Clin. Pharmacol., 52: 1927-1933 (2012).
12. Stockis, A., Sargentini-Maier, M. L. and Horsmans, Y.: Brivaracetam disposition in mild to severe hepatic impairment. J. Clin. Pharmacol., 53: 633-641 (2013).
13. Nicolas, J. M., Chanteux, H., Rosa, M., Watanabe, S. and Stockis, A.: Effect of gem fibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab. Dispos., 40: 1466-1472 (2012).
14. Sargentini-Maier, M. L., Espie, P., Coquette, A. and Stockis, A.: Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Dispos., 36: 36-45 (2008).
15. Whomsley, R., Dell'Aiera, S., Brochot, A., Espie, P. and Delepine, X.: Identification of the cytochrome P450 isoforms responsible for the hydroxylation of brivaracetam. AAPS J., 9: 3408 (2007).
16. Goldstein, J. A., Ishizaki, T., Chiba, K., de Morais, S. M., Bell, D., Krahn, P. M. and Evans, D. A.: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics, 7: 59-64 (1997).
17. Inomata, S., Nagashima, A., Itagaki, F., Homma, M., Nishimura, M., Osaka, Y., Okuyama, K., Tanaka, E., Nakamura, T., et al.: CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther., 78: 647-655 (2005).
18. Kimura, M., Ieiri, I., Mamiya, K., Urae, A. and Higuchi, S.: Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit., 20: 243-247 (1998).
19. Smith, B. P., Vandenhende, F. R., DeSante, K. A., Farid, N. A., Welch, P. A., Callaghan, J. T. and Forgue, S. T.: Confidence interval criteria for assessment of dose proportionality. Pharm. Res., 17: 1278-1283 (2000).
20. Bogman, K., Silkey, M., Chan, S. P., Tomlinson, B. and Weber, C.: Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. Eur. J. Clin. Pharmacol., 66: 1005-1015 (2010).